沃爾核材(002130.SZ):已立項研發PCIe 7.0高速通信線,目前已完成部分性能的測試
格隆匯7月7日丨沃爾核材(002130.SZ)在投資者互動平臺表示,第一、公司已立項研發PCIe 7.0高速通信線,目前已完成部分性能的測試。第二、藕芯結構技術與物理髮泡技術屬於兩種產品技術路線,性能指標各有優勢,無法簡單定義技術替代關係;公司224G高速通信線已經過客戶嚴格的認證審覈、現已穩定量產供應,該產品採用多種技術方案,包括物理髮泡技術、實心材料技術等;公司將緊跟行業前沿技術,不斷迭代、創新新產品,爲客戶提供全面解決方案。第三、公司多通道1.6T高速通信線已完成重要客戶的驗證,後續公司將結合市場客戶需求以及內部產能情況,合理調節資源、組織生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.